Is Entero Healthcar overvalued or undervalued?

As of 22 August 2025, Entero Healthcare's valuation grade has moved from attractive to very attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 52.27, an EV to EBITDA of 28.35, and a PEG Ratio of 0.37, which suggests that the stock may be undervalued relative to its growth prospects.
In comparison to its peers, Entero Healthcare's PE Ratio is substantially higher than TCS at 22.42 and Infosys at 22.67, indicating a premium valuation. However, its PEG Ratio of 0.37 is notably lower than TCS's 6.34 and Infosys's 10.16, suggesting that Entero may offer better growth potential relative to its price. Despite a recent decline in stock performance year-to-date, where it fell by 12.75% compared to a 4.05% gain in the Sensex, the underlying fundamentals and peer comparisons support the conclusion that Entero Healthcare is undervalued.